Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
Nicolette T MorrisJenny BrookAmi Ben-ArtziWilliam MartinTanaz A KermaniLynette Avedikian-TatosyanGeorge KarpouzasHimakar NagamGeraldine NavarroSoo ChoiMihaela B TaylorDavid ElashoffGurjit S KaeleyVeena K RanganathPublished in: Clinical rheumatology (2021)
ClinicalTrials.gov NCT01717859 Key Points • Over 90% of RA patients with baseline DAS28-ESR ≥ 4.4 and PDUS34 ≥ 10 required intravenous tocilizumab dose escalation from 4 to 8 mg/kg at 12 weeks. • Reduction in power Doppler ultrasonography (US34-PDUS) scores correlate with DAS28-ESR and CDAI over 24 weeks in rheumatoid arthritis patients with moderate to severe disease activity. • Baseline US34-PDUS predicts future improvements in clinical disease activity outcomes, independent of baseline DAS28-ESR. • Clinical response measures, DAS28-ESR and CDAI, improved across US34-PDUS 20/50/70 categories, while patient-reported outcomes did not.
Keyphrases
- disease activity
- rheumatoid arthritis patients
- rheumatoid arthritis
- systemic lupus erythematosus
- estrogen receptor
- ankylosing spondylitis
- patient reported outcomes
- juvenile idiopathic arthritis
- magnetic resonance imaging
- high dose
- interstitial lung disease
- blood flow
- open label
- metabolic syndrome
- high intensity
- computed tomography
- systemic sclerosis
- gestational age
- skeletal muscle
- type diabetes